10x Genomics Stock News

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

10x Genomics Inc - Class A (TXG) shares closed today 11.8% lower than it did at the end of yesterday. The stock is currently down 29.6% year-to-date, down 40.3% over the past 12 months, and up 98.7% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $135.47 and as low as $104.69 this week.Shares closed 49.8% below its 52-week high and 0.1% above its 52-week low.Trading volume this week was 0.7% higher than the 10-day average and 55.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 145.9% The company's stock price performance over the past 12 months lags the peer average by 149.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

10x Genomics Inc - Class A (TXG) shares closed today at 0.1% above its 52 week low of $104.69, giving the company a market cap of $9B. The stock is currently down 29.6% year-to-date, down 40.3% over the past 12 months, and up 98.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 55.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 145.9% The company's stock price performance over the past 12 months lags the peer average by 149.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

10x Genomics Inc - Class A (TXG) shares closed today at 1.5% above its 52 week low of $117.01, giving the company a market cap of $11B. The stock is currently down 18.1% year-to-date, down 27.2% over the past 12 months, and up 131.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 116.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 81.4% The company's stock price performance over the past 12 months lags the peer average by 118.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PUNE, India, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Global Next Generation Sequencing (NGS) Market is growing with a CAGR of 17.1% in the forecast period of 2022 to 2029 and is expected to reach USD 29,307.13 Million by 2029. The most appropriate, exclusive, realistic, and admirable Next Generation Sequencing (NGS) Market Research Report is delivered with devotion depending upon the business needs. With the precise base year and the historic year, estimations and calculations are performed in this industry report. Market share analysis and key trend analysis are the key accomplishing factors in this market report. Report helps to recognize how the market is going to perform in the forecast years by giving information about market definition, classifications, applications, and engagements. DBMR team provides Next Generation Sequencing (NGS) Market research report with loyalty that is promising and the way in which expected. Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-next-generation-sequencing-ngs-market Key Companies operating in the Next Generation Sequencing (NGS) Market are: Agilent Technologies Inc Thermo Fisher Scientific Inc QIAGEN Illumina Inc Bio-Rad Laboratories Inc Roche Sequencing (A subsidiary of F.

10x Genomics <> turned lower in afternoon trading after the companys management highlighted COVID-19 impact and supply chain issues.At the ongoing 40th Annual J.P

10x Genomics Inc - Class A (TXG) shares closed today at 1.7% above its 52 week low of $125.60, giving the company a market cap of $11B. The stock is currently down 14.2% year-to-date, down 19.8% over the past 12 months, and up 142.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 22.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 11.9% The company's stock price performance over the past 12 months lags the peer average by 47.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PLEASANTON, Calif., Dec. 22, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the company will be participating in the upcoming 40th Annual J.P.

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

Understanding the State of the Genomics Market

The Genomics provides an overview of the complete set of genetic commands provided by the DNA, while transcriptomics looks into gene appearance patterns. The studies of all genes and their associated mRNAs are correspondingly called genomics and transcriptomics. Genomics reveals

DekaBank Deutsche Girozentrale raised its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 560.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 45,379 shares of the companys stock after acquiring an additional 38,505 shares during the quarter. DekaBank Deutsche Girozentrales holdings in 10x Genomics were []

10x Genomics Inc. (NASDAQ:TXG) price on Friday, December 10, fall -2.83% below its previous days close as a downside momentum from buyers pushed the stocks value to $139.51. A look at the stocks price movement, the close in the last trading session was $143.57. Turning to its 52-week performance, $208.99 and $128.15 were the 52-week 10x Genomics Inc. (TXG) Price Target And Rating Are Reviewed By Analysts. Read More »

10x Genomics, Inc. (NASDAQ:TXG) CEO Serge Saxonov sold 15,000 shares of the stock in a transaction on Tuesday, December 7th. The stock was sold at an average price of $145.97, for a total transaction of $2,189,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this […]

ARLINGTON, Va., Dec. 8, 2021 /PRNewswire/ -- BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory firm serving the life science tools market, today announced that nine companies have been selected for a Life Science Industry Award for launching one of